Product Description
Mechanisms of Action: OPR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: South Africa
Approved Indications: None
Known Adverse Events: None
Company: Centre Hospitalier Universitaire de Saint Etienne
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT02112695 | N/A |
Completed |
Anorexia |
2017-07-06 |
|
| NCT02524301 | N/A |
Completed |
Body Dysmorphic Disorders|Anorexia |
2016-07-28 |